According to pharmalive.com, Cosette has appointed Andrew Adams as Vice President of Supply Chain & Sourcing.
Leadership Appointment Confirmed
The appointment was announced on September 10, 2026, at 9:42 am. This executive move follows a series of leadership updates reported by PharmaLive on the same date, including EVERSANA naming Stuart Diamond chief financial officer at 8:00 am and GBI Bio appointing Jesse McCool, Ph.D., as CEO at 8:50 am.
Andrew Adams joins Cosette amid heightened industry focus on supply chain resilience and strategic sourcing. His role directly supports Cosette’s operational infrastructure for pharmaceutical products, aligning with broader sector priorities highlighted across multiple PharmaLive reports dating back to March 9, 2011 and November 11, 2011.
The announcement appears in the context of ongoing coverage of pharmaceutical supply chain dynamics, including regional launch strategies influenced by Most Favored Nation (MFN) policy considerations reported on September 10, 2026 at 9:31 am.
Contextual Industry Reporting
PharmaLive’s coverage spans over a decade, with documented reports on global contract manufacturing published as early as November 11, 2011, and drug delivery analysis dated December 11, 2011. The outlet also tracks long-term trends such as OTC market review and outlook, first covered on March 9, 2011.
A recurring theme across these reports is the interdependence of regulatory compliance, clinical trial logistics, and end-to-end supply chain visibility — all areas falling under Adams’ new remit. The Cosette appointment coincides with industry-wide attention to manufacturing footprints, as seen in related coverage of AbbVie, AstraZeneca, and Bristol-Myers Squibb.
PharmaLive describes itself as the pharma industry’s destination for news and analysis, serving pharmaceutical and healthcare advertising and marketing professionals. Its reporting includes segments on drug pricing, patient access, and FDA regulatory approval processes — domains where supply chain integrity directly impacts outcomes.
Source: pharmalive.com
Compiled from international media by the SCI.AI editorial team.
